Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Brian Cole, MD, MBA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 1 original source on average. We currently track 1 Biotech story that mention Dr. Justin Newman, all published on July 22, 2026.
Last mentioned: Jul 22, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Brian Cole, MD, MBA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 1 original source on average. We currently track 1 Biotech story that mention Dr. Justin Newman, all published on July 22, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Justin Newman. Shared-story counts are live from our verified record — not editorial picks.
The first U.S. participant has been treated in MEDIPOST's Phase III trial of its allogeneic umbilical cord blood-derived MSC therapy for knee OA. The FDA agreed that this single pivotal study, supported by prior ex-U.S. Phase 3 data, may suffice for a BLA, positioning MEDIPOST at the forefront of regenerative medicine for osteoarthritis.
Source: philippinetimes.com
Dr. Justin Newman is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
